A Seeking Alpha analyst has reaffirmed a buy rating on Alcon (ALC) stock, highlighting its eyecare portfolio amid the abandoned acquisition of STAAR Surgical. The assessment points to resilience against market shocks and positive earnings forecasts for FY26.
Alcon's buy rating stands firm, driven by robust demand in the eyecare sector and a promising product pipeline, even after the company abandoned its planned acquisition of STAAR Surgical. The analyst notes ALC's potential to weather market shocks, supported by a favorable balance sheet and upbeat EPS projections for FY26. Wall Street consensus aligns with this bullish outlook, with the analyst's price target suggesting a 48% upside by FY26 from current levels. While ALC trails some peers in profitability metrics, its annual dividend yield of 0.43% benefits from a low payout ratio and history of dividend growth, bolstering the income case. Key risks include execution challenges, cost inflation, and potential price shocks from petroleum-derived products used in manufacturing. The analysis underscores Alcon's macro tailwinds in eyecare as a counterbalance to recent market volatility observed in early March. No positions were held by the analyst in ALC or related stocks at the time of writing.